- Home
- KROS vs BANX Comparison
KROS vs BANX Comparison
Compare KROS & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | BANX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 201.5M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | KROS | BANX |
|---|---|---|
| Price | $11.31 | $21.07 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.86 | N/A |
| AVG Volume (30 Days) | ★ 159.2K | 37.3K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $18.45 |
| 52 Week High | $22.55 | $23.67 |
Technical Indicators
Market Signals| Indicator | KROS | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 61.98 |
| Support Level | $10.57 | $21.01 |
| Resistance Level | $11.56 | $21.29 |
| Average True Range (ATR) | 0.48 | 0.25 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 55.91 | 72.34 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.